RCKT ROCKET PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ROCKET PHARMACEUTICALS INC reported revenue of $0, net income of $123M and diluted EPS of $1.08; over the last four quarters revenue was $0 and net income −$17.3M; for the fiscal year ended December 2025 revenue was $0.

RCKT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$232M, net income −$223M (margin n/a), EPS −$2.01
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$273M, net income −$259M (margin n/a), EPS −$2.73
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$260M, net income −$246M (margin n/a), EPS −$2.92
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$224M, net income −$222M (margin n/a), EPS −$3.26
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$167M, net income −$169M (margin n/a), EPS −$2.67

RCKT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income $123M, EPS $1.08
• Quarter ended Mar 31, 2026: revenue $0, net income −$47.6M, EPS −$0.42
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$42.5M, EPS −$0.38
• Quarter ended Sep 30, 2025: revenue $0, net income −$50.3M, EPS −$0.45
• Quarter ended Jun 30, 2025: revenue $0, net income −$68.9M, EPS −$0.62
• Quarter ended Mar 31, 2025: revenue $0, net income −$61.3M, EPS −$0.56
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$60.3M, EPS −$0.62
• Quarter ended Sep 30, 2024: revenue $0, net income −$66.7M, EPS −$0.71
• Quarter ended Jun 30, 2024: revenue $0, net income −$69.6M, EPS −$0.74
• Quarter ended Mar 31, 2024: revenue $0, net income −$62.1M, EPS −$0.66
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$59.7M, EPS −$0.62
• Quarter ended Sep 30, 2023: revenue $0, net income −$61.9M, EPS −$0.75
• Quarter ended Jun 30, 2023: revenue $0, net income −$65.7M, EPS −$0.82
• Quarter ended Mar 31, 2023: revenue $0, net income −$58.3M, EPS −$0.73
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$66.7M, EPS −$0.89
• Quarter ended Sep 30, 2022: revenue $0, net income −$57.8M, EPS −$0.87
• Quarter ended Jun 30, 2022: revenue $0, net income −$54.4M, EPS −$0.83
• Quarter ended Mar 31, 2022: revenue $0, net income −$43.0M, EPS −$0.67
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$44.2M, EPS −$0.68
• Quarter ended Sep 30, 2021: revenue $0, net income −$50.1M, EPS −$0.79

RCKT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$190M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$210M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$195M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$178M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$121M, share buybacks $0

RCKT balance sheet

• Jun 30, 2026: cash $225M, total assets $423M, total liabilities $54.3M, shareholders' equity $369M
• Mar 31, 2026: cash $49.6M, total assets $285M, total liabilities $47.4M, shareholders' equity $238M
• Dec 31, 2025: cash $77.6M, total assets $330M, total liabilities $53.2M, shareholders' equity $277M
• Sep 30, 2025: cash $75.9M, total assets $368M, total liabilities $54.4M, shareholders' equity $314M
• Jun 30, 2025: cash $32.8M, total assets $421M, total liabilities $66.8M, shareholders' equity $354M
• Mar 31, 2025: cash $49.8M, total assets $471M, total liabilities $58.9M, shareholders' equity $412M
• Dec 31, 2024: cash $164M, total assets $528M, total liabilities $64.5M, shareholders' equity $463M
• Sep 30, 2024: cash $65.6M, total assets $394M, total liabilities $63.9M, shareholders' equity $330M

What is RCKT's revenue?

ROCKET PHARMACEUTICALS INC reported $0 of revenue over its last four quarters, through June 30, 2026.

Is RCKT profitable?

No. ROCKET PHARMACEUTICALS INC lost $17.3M over the last four quarters.

What is RCKT's EPS?

Diluted earnings per share over the last four quarters were −$0.17; $1.08 in the latest quarter.

RCKT ownership and insider trades · All stocks